title: Tołpa Torf Preparation (TTP) induces interferon and tumor necrosis factor production in human peripheral blood leukocytes.
abstract: Tołpa Torf Preparation (TTP) is a natural immunomodulating drug registered in Poland for use in humans. TTP is a biologically active low molecular weight fraction of an extract from peat containing organic substances, primary bound sugars, amino-acids, uronic and huminic acids and mineral salts. The toxicity of TTP is remarkably low, eg. cytotoxicity (CD50) for human peripheral blood leukocytes (PBL) is 1-9 mg/ml. We have discovered that TTP is an interferon (IFN) and tumor necrosis factor (TNF) inducer in human PBL. The IFN and TNF response of the PBL cultures was dose dependent. The optimal concentration of TTP for IFN or TNF response was 10-100 micrograms/ml. The cytokines stimulated by TTP were IFN-gamma, IFN-alpha and TNF-alpha. Ten commercial batches of TTP have been found to be active as cytokines inducers although variations in their activities were observed. On the other hand, 8 batches of TTP rejected by the producer because of the inadequate immunostimulating activity determined in mice, were found to be significantly less active than the commercial preparations. Over 115 buffy coats from the individual blood donors were used to prepare PBL cultures for this study. Approximately 20% of the PBL cultures were unresponsive to TTP. The IFN and TNF response of PBL to other inducers: phytohemagglutinin (PHA) or lipopolysaccharides (LPS) also varied. Whereas only 7% of PBL could not be stimulated by PHA, as much as 20-50% of PBL failed to produce IFN or TNF when treated with LPS. We suggest that TTP may have clinically useful activities connected with the capacity of stimulation of IFNs and TNF production.
authors.affiliation: Laboratory of Virology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław.
authors.forename: A D
authors.initials: AD
authors.lastname: Inglot
authors.forename: J
authors.initials: J
authors.lastname: Zielińska-Jenczylik
authors.forename: E
authors.initials: E
authors.lastname: Piasecki
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000596:Amino Acids / Q000494:pharmacology*; D002241:Carbohydrates / Q000494:pharmacology*; D002478:Cells, Cultured; D004338:Drug Combinations; D006801:Humans; D006812:Humic Substances / Q000494:pharmacology*; D007369:Interferon Inducers / Q000494:pharmacology*; D007372:Interferons / Q000096:biosynthesis*; D007962:Leukocytes / Q000276:immunology*; D012987:Soil / Q000032:analysis*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*; D014574:Uronic Acids / Q000494:pharmacology*
chemical_list: D000276:Adjuvants, Immunologic; D000596:Amino Acids; D002241:Carbohydrates; D004338:Drug Combinations; D006812:Humic Substances; D007369:Interferon Inducers; D012987:Soil; C084029:Tolpa; D014409:Tumor Necrosis Factor-alpha; D014574:Uronic Acids; D007372:Interferons